Petroleo Brasileiro SA Petrobras
PBR
Strategy
MSTR
Vale SA
VALE
KB Home
KBH
Apple
AAPL
US Stock MarketDetailed Quotes
HOOK HOOKIPA Pharma
- 1.890
- -0.010-0.53%
Close Feb 14 16:00 ET
- 1.760
- -0.130-6.88%
Post 20:01 ET
18.70MMarket Cap-0.51P/E (TTM)
1.950High1.841Low47.71KVolume1.880Open1.900Pre Close90.28KTurnover1.00%Turnover RatioLossP/E (Static)9.89MShares10.50052wk High0.26P/B9.06MFloat Cap1.65052wk Low--Dividend TTM4.79MShs Float200.000Historical High--Div YieldTTM5.73%Amplitude1.650Historical Low1.892Avg Price1Lot Size
Trending Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
HOOKIPA Pharma Stock Forum
HOOKIPA Pharma Announces Enrollment Completion of Phase 1b Clinical Trial Evaluating HB-500 for the Treatment of HIV
3 minutes ago, 4:00 AM PST
Via GlobeNewswire
HOOK
Share
HB-500 is a next-generation therapeutic vaccine being developed in collaboration with Gilead Sciences, Inc. (Gilead) as a potential component of a curative regimen for human immunodeficiency virus (HIV)
Under the collaboration agreement, HOOKIPA is responsible for advancing the HIV program throug...
Poolbeg Pharma and HOOKIPA Pharma have provided an update on their potential combination, following announcements from January 2 and 7, 2025. The key update concerns Gilead Sciences' participation in the proposed concurrent Fundraise. Gilead has expressed its intention to:
1. Vote in alignment with HOOKIPA Board's recommendation if a formal offer is m...
Poolbeg Pharma plc (“Poolbeg”) and HOOKIPA Pharma Inc. (“HOOKIPA”) Update on Potential Combination of Poolbeg and HOOKIPA
Poolbeg Pharma and HOOKIPA Pharmahave provided an update on their potential combination, following announcements from January 2 and 7, 2025. The key update concerns Gilead Sciences' participation in the proposed concurrent Fundraise. Gilead has expressed its intention to:
1. Vote in alignment with HOOKIPA Board's recommendation if a formal offer ...
Poolbeg Pharma plc (“Poolbeg”) and HOOKIPA Pharma Inc. (“HOOKIPA”) Update on Potential Combination of Poolbeg and HOOKIPA
Poolbeg Pharma and HOOKIPA Pharma have announced important updates regarding their potential combination. Gilead Sciences, a significant HOOKIPA shareholder owning 19.4% (1,875,947 shares) of HOOKIPA's issued share capital, has indicated its intention to vote in line with HOOKIPA Board's recommendation for a formal offer and participate in the ...
M&A Expert:positive
This amendment to HOOKIPA's Rule 2.4 announcement reveals critical details about a potential business combination with Poolbeg Pharma plc. The correction of HOOKIPA's ISIN code (US43906K2096) reflects their July 2024 1-for-10 reverse stock split. The company's current capital structure includes 9,655,022 common shares, 2,399,517 Class A common shares and various ser...
$Draganfly (DPRO.US)$ i think this will get back into the trend it was ...
No comment yet